Fulltext

Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis

Hegazi OE 1 , Alalalmeh SO 1 , Shahwan M 1 , Jairoun AA 2 , Alourfi MM 3 , Bokhari GA 4 Show all authors , Alkhattabi A 4 , Alsharif S 5 , Aljehani MA 6 , Alsabban AM 7 , Almtrafi M 7 , Zakri YA 7 , AlMahmoud A 8 , Alghamdi KM 8 , Ashour AM 9 , Alorfi NM 9

Affiliations 

  • 1 Center of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates
  • 2 Health and Safety Department, Dubai, United Arab Emirates
  • 3 Internal medicine Department, King Faisal Medical City for Southern Region, Abha, Saudi Arabia
  • 4 Department of gastroenterology, East Jeddah hospital, Jeddah, Saudi Arabia
  • 5 Gastroenterology Department, Armed force Hospital of southern region, Khamis Mushait, Saudi Arabia
  • 6 Division of Gastroenterology, Department of Medicine, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
  • 7 Gastroenterology Section, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia
  • 8 Gastroenterology Section, Internal Medicine Department, King Fahad Hospital, Jeddah, Saudi Arabia
  • 9 Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
Diabetes Metab Syndr Obes, 2024;17:545-561.
PMID: 38327733 DOI: 10.2147/DMSO.S448476

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common disease and has been increasing in recent years. To date, no FDA-approved drug specifically targets NAFLD.

METHODS: The terms "Non-alcoholic Fatty Liver Disease" and "NAFLD" were used in a search of ClinicalTrials.gov on August 24, 2023. Two evaluators independently examined the trials using predetermined eligibility criteria. Studies had to be interventional, NAFLD focused, in Phase IV, and completed to be eligible for this review.

RESULTS: The ClinicalTrials.gov database was searched for trials examining pharmacotherapeutics in NAFLD. The search revealed 1364 trials, with 31 meeting the inclusion criteria. Out of these, 19 were finalized for evaluation. The dominant intervention model was Parallel. The most prevalent studies were in Korea (26.3%) and China (21.1%). The most common intervention was metformin (12.1%), with others like Exenatide and Pioglitazone accounting for 9.1%.

CONCLUSION: Therapeutics used to manage NAFLD are limited. However, various medications offer potential benefits. Further investigations are definitely warranted.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications